_targeting the MAPK Pathway in KRAS-Driven Tumors
- PMID: 32289276
- DOI: 10.1016/j.ccell.2020.03.013
_targeting the MAPK Pathway in KRAS-Driven Tumors
Abstract
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as _targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key _target to block KRAS-mutant cancers.
Keywords: KRAS-driven cancer; MAPK pathway; clinical trials; lung adenocarcinoma; pancreatic ductal adenocarcinoma.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
An integrative pharmacogenomics analysis identifies therapeutic _targets in KRAS-mutant lung cancer.EBioMedicine. 2019 Nov;49:106-117. doi: 10.1016/j.ebiom.2019.10.012. Epub 2019 Oct 23. EBioMedicine. 2019. PMID: 31668570 Free PMC article.
-
_targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2. Adv Cancer Res. 2022. PMID: 35101228
-
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Cancer Res. 2007 May 15;67(10):4933-9. doi: 10.1158/0008-5472.CAN-06-4592. Cancer Res. 2007. PMID: 17510423
-
_targeting KRAS mutant lung cancer: light at the end of the tunnel.Mol Oncol. 2022 Mar;16(5):1057-1071. doi: 10.1002/1878-0261.13168. Epub 2022 Jan 18. Mol Oncol. 2022. PMID: 34951114 Free PMC article. Review.
-
_targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7. J Intern Med. 2020. PMID: 32176377 Review.
Cited by
-
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10. Proc Natl Acad Sci U S A. 2020. PMID: 32913049 Free PMC article.
-
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.Cell Rep Med. 2022 Nov 15;3(11):100815. doi: 10.1016/j.xcrm.2022.100815. Cell Rep Med. 2022. PMID: 36384095 Free PMC article.
-
Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis.Cells. 2024 Feb 6;13(4):298. doi: 10.3390/cells13040298. Cells. 2024. PMID: 38391911 Free PMC article.
-
PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer.Cell Death Discov. 2024 Jan 5;10(1):7. doi: 10.1038/s41420-023-01771-w. Cell Death Discov. 2024. PMID: 38182573 Free PMC article.
-
Evidence of the Beneficial Effects of Ursolic Acid against Lung Cancer.Molecules. 2022 Nov 2;27(21):7466. doi: 10.3390/molecules27217466. Molecules. 2022. PMID: 36364289 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
